Try our Advanced Search for more refined results
June 07, 2017
Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc.
Case Number:
17-2134
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
January 04, 2019
Full Fed. Circ. Won't Revisit 'Blocking Patent' Ruling
The Federal Circuit on Friday said it wouldn't reconsider the invalidation of four patents covering Acorda Therapeutics Inc.'s flagship multiple sclerosis drug Ampyra, despite the drugmaker's argument that the decision had "radically expand[ed]" the so-called blocking patent doctrine.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login